Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isobiotic AI4 is a probiotic food supplement developed by ISOMED PHARMA, formulated to support the recovery of intestinal homeostasis in patients experiencing dysbiosis or mucosal inflammation. The product contains a combination of four probiotic lactic ferment strains—Lactobacillus acidophilus (SGL 11), Bifidobacterium longum spp longum (SGB 05), Bifidobacterium longum spp infantis (SGB 03), and Lactobacillus plantarum (SGL 07)—alongside two phytotherapeutic extracts. These include fennel (Foeniculum vulgare) titrated to 0.5% essential oil, which provides carminative properties, and turmeric (Curcuma longa) titrated to 95% curcuminoids, which offers anti-inflammatory benefits. It is administered orally to restore intestinal balance and gut microflora.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isobiotic AI4.